AstraZeneca Sweden

Last updated: 03.10.2019

company_picture

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas – Oncology, Cardiovascular & Metabolic Disease and Respiratory. We are also selectively active in the areas of autoimmunity, neuroscience and infection.

AstraZeneca is one of Sweden’s most important export companies with operations in Gothenburg and Södertälje. We are about 6 900 people working on research, production and marketing of medicines. Every year we make extensive investments in Sweden, in addition to ongoing R&D and production costs.

In our manufacturing in Sweden, we have made large construction investments in recent years; during the period 2010-2018 approximately SEK 8.7 billion. For the coming years, we plan annual investments of about SEK 1.5 billion (biological production plant not included).

We have invested about SEK 2.5 billion in a new high-tech plant for the production of biological drugs in Gärtuna. The new facility will focus on filling and packaging of protein drugs. It will be ready to deliver commercial products in the first half of 2020. In Gothenburg, we have invested approximately SEK 1.5 billion since 2010 to develop the research facility. Since 2010, we have also invested approximately SEK 1.4 billion in academic collaborations in Sweden.

 

Contact

Astraallén, 151 85 Södertälje, Sweden

Tel: 08 553 260 00

astrazeneca.se

Related

We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here